Roza Seidakhmetova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roza Seidakhmetova has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aikorkem Kyzkenova
School of Pharmacy, Karaganda Medical University, Karaganda 100008, Kazakhstan
1 shared publication - Khorlan Itzhanova
School of Pharmacy, Karaganda Medical University, Karaganda 100008, Kazakhstan
1 shared publication - Pernesh Bekisheva
School of Pharmacy, Karaganda Medical University, Karaganda 100008, Kazakhstan
1 shared publication - Zhangeldy Nurmaganbetov
School of Pharmacy, Karaganda Medical University, Karaganda 100008, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 19 October 2026
- Published by MDPI AG in Chemistry Proceedings
- Vol. 23 (1) , 1
Synthesis and Antiviral Activity of 1-(4-Pyridin-2-yl-[1,2,3]triazol-1-ylmethyl)-octahydro-quinolizine
The antiviral activity of compound (5) was demonstrated by a reduction in influenza A viral infectivity of 2.0 log10 for H3N2 (99% inactivation) and 1.9 log10 for H1N1 (98.7% inactivation) at a dose of 0.4 mg/embryo. The compound demonstrated no noticeable embryotoxicity at the maximum tested dose of 0.4 mg/embryo, while the LD50 was not reached within the investigated concentration range. Notably, its therapeutic index outperforms rimantadine and oseltamivir. Furthermore, a scalable 8-stage laboratory production protocol was successfully validated. These findings position compound (5) as a highly promising, low-toxicity domestic prototype for the development of innovative, multi-targeted anti-influenza pharmaceutical drugs.
- 19 October 2026
- Published by MDPI AG in Chemistry Proceedings
- Vol. 23 (1) , 1
Open AccessSynthesis and Antiviral Activity of 1-(4-Pyridin-2-yl-[1,2,3]triazol-1-ylmethyl)-octahydro-quinolizine
The antiviral activity of compound (5) was demonstrated by a reduction in influenza A viral infectivity of 2.0 log10 for H3N2 (99% inactivation) and 1.9 log10 for H1N1 (98.7% inactivation) at a dose of 0.4 mg/embryo. The compound demonstrated no noticeable embryotoxicity at the maximum tested dose of 0.4 mg/embryo, while the LD50 was not reached within the investigated concentration range. Notably, its therapeutic index outperforms rimantadine and oseltamivir. Furthermore, a scalable 8-stage laboratory production protocol was successfully validated. These findings position compound (5) as a highly promising, low-toxicity domestic prototype for the development of innovative, multi-targeted anti-influenza pharmaceutical drugs.